Edition:
United Kingdom

Gilead Sciences Licenses Respiratory, Herpes Antiviral Research Programs From Novartis


Friday, 19 Jul 2019 

July 19 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES LICENSES RESPIRATORY AND HERPES ANTIVIRAL RESEARCH PROGRAMS FROM NOVARTIS.GILEAD SCIENCES INC - GILEAD WILL ACQUIRE EXCLUSIVE GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE NOVEL SMALL MOLECULES AGAINST THREE UNDISCLOSED TARGETS.GILEAD-NOVARTIS TO RECEIVE UPFRONT PAYMENT & IS ELIGIBLE TO RECEIVE UP TO $291 MILLION IN MILESTONE PAYMENTS UPON ACHIEVEMENT OF CERTAIN MILESTONES.GILEAD SCIENCES - NOVARTIS IS ALSO ELIGIBLE TO RECEIVE ROYALTIES ON ANNUAL NET SALES UNDER AGREEMENT.